Virpax PharmaceuticalsNASDAQ: VRPX

Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical nonsteroidal anti-inflammatory drug treatment for chronic osteoarthritis of the knee; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company's preclinical stage product candidates also comprise PES200, which enables the delivery of a metabolically labile peptide drug into the brain; AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and VRP324, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.

Virpax Pharmaceuticals is in the Healthcare sector

Virpax Pharmaceuticals is in the Biotechnology industry

Virpax Pharmaceuticals is headquartered in United States

Virpax Pharmaceuticals initial public offering (IPO) was on 17 February 2021

https://www.virpaxpharma.com

No, Virpax Pharmaceuticals is not included in the S&P 500 index

No, Virpax Pharmaceuticals is not included in the NASDAQ 100 index

No, Virpax Pharmaceuticals is not included in the Dow Jones index